Analyst firms · Truist Securities · PCRX

Truist Securities PCRX price target and rating history

Pacira BioSciences Inc. (PCRX) · Health Care

Truist Securities rates Pacira BioSciences Inc. (PCRX) Buy with a $30 price target, as of its latest action on Aug 17, 2026. It has published 4 rating actions on PCRX since August 2024, including 2 upgrades and 1 downgrade. Across 4 firms with a PCRX price target in the last 12 months, the median target is $29. Truist Securities's $30 is 3% above that.

Current rating
Buy
Price target
$30
Median target, all firms
$29
Actions on PCRX
4

Truist Securities price target on PCRX

$30$19$820252026
Truist Securities price target on PCRX, each point a stated target, August 2024 to August 2026.

Every Truist Securities rating on PCRX

How other firms rate PCRX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
OppenheimerOutperform$32Sep 23, 2026
Leerink PartnersMarket Perform$28Sep 9, 2026
Truist SecuritiesBuy$30Aug 17, 2026
BarclaysEqual Weight$27Dec 9, 2025

Questions about Truist Securities and PCRX

What is Truist Securities's price target for PCRX?
Truist Securities's latest stated price target for Pacira BioSciences Inc. (PCRX) is $30, from its action on Aug 17, 2026.
What is Truist Securities's rating on PCRX?
Truist Securities rates PCRX Buy, a bullish rating, as of Aug 17, 2026.
When did Truist Securities last change its view on PCRX?
On Aug 17, 2026, Truist Securities resumes coverage at Buy, price target $30.
How does Truist Securities's PCRX target compare with other analysts?
Across 4 firms with a PCRX price target in the last 12 months, the median target is $29. Truist Securities's $30 is 3% above that.

More PCRX rating histories

All Truist Securities ratingsPCRX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.